• Newly diagnosed or recurrent malignant brain tumor patients
• Primary or metastatic malignant brain tumor patients 

The Brain Tumor Team at Linkou Chang Gung Memorial Hospital is dedicated to precision medicine for malignant brain tumors, integrating personalized surgery, translational research, and clinical trials. Clinically, the team has established a multidisciplinary collaborative model and has standardized awake craniotomy procedures, delivering efficient and safe surgical care. With over 120 brain tumor surgeries performed annually—leading the nation—the resection rate exceeds 95%. Among patients with low-grade gliomas, more than 80% maintain or improve neurological function one year after surgery. In research, the team has independently developed the NaviFUS focused ultrasound system for blood-brain barrier opening and drug delivery and is actively advancing multiple clinical trials. International translational research collaborations have been established with National Taiwan University, UCSF, University of Virginia and Stanford University. Academically, the team has published over 130 SCI-indexed papers in the past decade, covering tumor molecular markers, nanomedicine, and focused ultrasound. Its total citations and H-index rank among the highest in Asia. In terms of clinical trials, the team has initiated a globally leading clinical trial of focused ultrasound for brain treatment, which has advanced to Phase III. The team also leads over 80% of domestic clinical trials involving new drugs and innovative therapies for malignant brain tumors, and has further internationalized trials of domestically developed drugs, promoting Taiwan’s pharmaceutical innovations for global application. Upholding the principles of evidence-based practice, clinical excellence, and global engagement, the team continues to translate innovation into clinical applications, improve patient outcomes and quality of life, and position Taiwan as a leader in global brain tumor care.

• Personalized Surgery for Malignant Brain Tumors: 

a. Widely applied to newly diagnosed and recurrent gliomas

b. Widely applied across gliomas of different malignancy grades

c. Comprehensive surgical planning integrating cognitive function, tumor parameters, and patient characteristics. 

• Innovative Translational Research & Development: 

a. Blood–brain barrier (BBB) opening

b. Adjunct approaches to brain tumor radiotherapy

c. Sonodynamic therapy for brain tumors

d. BBB opening–assisted liquid biopsy for brain diseases

• Clinical Trials to Benefit Patients: 

a. Focused ultrasound clinical trials

b. Novel drug clinical trials

c. Cell therapy clinical trials.